Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ICU Stock Forecast 2025-2026
$0.36
Current Price
$12.98M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ICU Price Targets
+178.2%
To High Target of $1.00
+178.2%
To Median Target of $1.00
+178.2%
To Low Target of $1.00
ICU Price Momentum
+12.5%
1 Week Change
-26.5%
1 Month Change
-84.0%
1 Year Change
-81.4%
Year-to-Date Change
-88.3%
From 52W High of $3.07
+24.0%
From 52W Low of $0.29
📊 TOP ANALYST CALLS
Did ICU Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if SeaStar is one of their latest high-conviction picks.
Latest ICU Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, ICU has a bullish consensus with a median price target of $1.00 (ranging from $1.00 to $1.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.36, the median forecast implies a 178.2% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICU Analyst Ratings
1
Buy
0
Hold
0
Sell
ICU Price Target Range
Low
$1.00
Average
$1.00
High
$1.00
Current: $0.36
Latest ICU Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICU.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 20, 2023 | Maxim Group | Anthony Vendetti | Buy | Initiates | $5.00 |
Seastar Medical Holding Corporation (ICU) Competitors
The following stocks are similar to SeaStar based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Seastar Medical Holding Corporation (ICU) Financial Data
Seastar Medical Holding Corporation has a market capitalization of $12.98M with a P/E ratio of -0.1x. The company generates $881,000 in trailing twelve-month revenue with a 100.0% profit margin.
Revenue growth is +169.1% quarter-over-quarter, while maintaining an operating margin of -1,955.7% and return on equity of -290.4%.
Valuation Metrics
Market Cap
$12.98M
Enterprise Value
$-804,055
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
13.9x
Growth & Margins
Revenue Growth (YoY)
+169.1%
Gross Margin
+92.3%
Operating Margin
-1,955.7%
Net Margin
+100.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+106.3%
Current Ratio
3.7x
Debt/Equity
0.0x
ROE
-290.4%
ROA
-86.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Seastar Medical Holding Corporation (ICU) Business Model
About Seastar Medical Holding Corporation
What They Do
Develops medical devices for critical care solutions.
Business Model
Seastar Medical generates revenue by developing and commercializing innovative medical devices aimed at treating life-threatening conditions such as acute kidney injury and sepsis. The company collaborates with healthcare institutions to create effective therapies, focusing on rigorous regulatory compliance and clinical validation to ensure the efficacy and safety of its products.
Additional Information
Headquartered in the United States, Seastar Medical is positioned in a high-stakes market that addresses significant unmet medical needs. Its commitment to enhancing patient outcomes through advanced therapies marks it as a significant player in the healthcare technology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
19
CEO
Mr. Eric Schlorff
Country
United States
IPO Year
2022
Website
seastarmedical.comSeastar Medical Holding Corporation (ICU) Latest News & Analysis
Latest News
Quick Summary
The FDA has reduced the surveillance requirement for HDE approval from 300 to 50 patients after reviewing data from the first 21 patients in the SAVE Registry.
Why It Matters
The FDA's reduced surveillance requirement may accelerate market entry for medical devices, potentially boosting stock prices for companies involved in the affected products.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) CEO Eric Schlorff will present at the NobleCon21 conference on December 3, 2025, at 4:00 PM EST. Investors are invited to attend.
Why It Matters
SeaStar Medical's CEO presenting at a prominent conference signals potential growth and investment interest, highlighting advancements in critical healthcare solutions, which may attract investor attention.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) appointed Michael Messinger as Chief Financial Officer. He has over 25 years of experience in the healthcare industry.
Why It Matters
The appointment of a seasoned CFO could enhance SeaStar Medical's financial strategy and governance, influencing investor confidence and potentially impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates
24 days ago
Quick Summary
SeaStar Medical announced the adoption of QUELIMMUNE therapy by three top children's hospitals for pediatric AKI, raised $12.4 million for operations, and updated on clinical trials.
Why It Matters
Adoption of QUELIMMUNE therapy by top hospitals and positive survival results enhance credibility, while the capital raise strengthens financial stability, signaling growth potential for SeaStar Medical.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SeaStar Medical Holdings (Nasdaq: ICU) will report Q3 financial results on November 13, 2025, after market close, followed by a webcast and conference call to discuss outcomes and business progress.
Why It Matters
SeaStar's upcoming financial results and conference call may influence investor sentiment, impacting stock performance and providing insights into the company's growth and market strategy.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Recent data indicate a high level of safety with no device-related adverse events and strong survival rates extending to 90 days, consistent with clinical trial results.
Why It Matters
Positive clinical trial results and strong safety data indicate potential for product approval and market success, boosting investor confidence and likely enhancing stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ICU Stock
What is Seastar Medical Holding Corporation's (ICU) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Seastar Medical Holding Corporation (ICU) has a median price target of $1.00. The highest price target is $1.00 and the lowest is $1.00.
Is ICU stock a good investment in 2026?
According to current analyst ratings, ICU has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ICU stock?
Wall Street analysts predict ICU stock could reach $1.00 in the next 12 months. This represents a 178.2% increase from the current price of $0.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Seastar Medical Holding Corporation's business model?
Seastar Medical generates revenue by developing and commercializing innovative medical devices aimed at treating life-threatening conditions such as acute kidney injury and sepsis. The company collaborates with healthcare institutions to create effective therapies, focusing on rigorous regulatory compliance and clinical validation to ensure the efficacy and safety of its products.
What is the highest forecasted price for ICU Seastar Medical Holding Corporation?
The highest price target for ICU is $1.00 from at , which represents a 178.2% increase from the current price of $0.36.
What is the lowest forecasted price for ICU Seastar Medical Holding Corporation?
The lowest price target for ICU is $1.00 from at , which represents a 178.2% increase from the current price of $0.36.
What is the overall ICU consensus from analysts for Seastar Medical Holding Corporation?
The overall analyst consensus for ICU is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $1.00.
How accurate are ICU stock price projections?
Stock price projections, including those for Seastar Medical Holding Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 8:48 AM UTC